echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Why did the stock price of the leading company get the orphan drug identification?

    Why did the stock price of the leading company get the orphan drug identification?

    • Last Update: 2021-12-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Event: Recently, GRCL.


    Why did the market react to the ups and downs of Genxi's product?

    01 Bringing hope to patients who have not met their clinical needs

    01 Bringing hope to patients who have not met their clinical needs

    Multiple myeloma is still a problem that the medical community has not found the best solution


    The drug has not yet been declared in China, but the FIC Intelligence database of Zhongkang shows that 3 international clinical registration numbers indicate that GC012F is conducting multi-center, phase I clinical trials initiated by investigators in China, including new cases of multiple myeloma And clinical trials in high-risk patients


    Source: Zhongkang FIC Intelligence database

    Prior to this, Genxi Biosciences has announced the latest clinical research progress of GC012F in the treatment of relapsed/refractory multiple myeloma at a number of top international academic conferences


    02 Proprietary technology shortens production time and reduces costs

    02 Proprietary technology shortens production time and reduces costs

    Conventional autologous CAR-T cell therapy takes a long time to prepare and is difficult to produce on a large scale, resulting in high prices and poor patient accessibility


    The company's other general-purpose CAR-T technology that can achieve large-scale production is also the industry's research and development trend.


    03 There is not much market space imaginable in the future

    03 There is not much market space imaginable in the future

    Approximately 160,000 patients are diagnosed with multiple myeloma every year, among which high-risk patients account for 20%-30%.


    And Genxi Bio, which was established in 2017, was listed on the US stock market in January this year, and no commercial product has been launched yet


    Source: Company's official website

    04 Conclusion

    04 Conclusion

    Genxi Bio’s product pipeline has disclosed 5 CAR-T product therapies.


    Zhongkang FIC Intelligence is an analytical database that assists companies in making varieties improvement and innovation decisions


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.